Company developing NRX-101 – first potential treatment for Acute Suicidal Ideation in Bipolar Depression Wilmington, Delaware & Tel Aviv, Israel , Feb. 10, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, Ph.D., M.D., Chief Executive Officer, […]

Clinical stage biopharma company advances development of first-in-class drug to decrease the risk of suicide in those suffering from bipolar depression SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ — Biotech Showcase at the JP Morgan Healthcare Conference NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB) in Bipolar […]

Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression WILMINGTON, Del. and TEL AVIV, Israel, Oct. 18, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing NRX-101 (CycluradTM), a first-in-class potentially breakthrough oral drug for the treatment of Acute Suicidal Ideation in […]

WILMINGTON, Del. and HAIFA, Israel, Sept 7, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing CycluradTM, a first-in-class, potentially breakthrough drug for the prevention of suicide in bipolar depression, announced today that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., […]

Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression TEL AVIV, Israel–(BUSINESS WIRE)– NeuroRx, a clinical-stage pharmaceutical company developing a first-in-class potentially breakthrough drug for the prevention of suicide in bipolar depression, was awarded first prize in the annual startup […]

Findings note the transient nature of ketamine effects and paucity of promising experimental NMDA antagonists WILMINGTON, Delaware, October 21, 2015 /PRNewswire/ — The active ingredient of Cyclurad™ by NeuroRx, Inc has been identified as potentially promising in the treatment of depression in this month’s report by the American Psychiatric Association Task Force on Novel Biomarkers […]

Journal of Clinical Psychiatry publishes initial report of human study which showed 50% reduction in symptoms of depression and 75% reduction in suicidality NEW YORK, June 24, 2015 /PRNewswire/ — NeuroRx, Inc., a clinical phase pharmaceutical company, reports first-in-man efficacy data for a newly-purposed class of drugs targeted towards rapidly reducing symptoms of depression and […]